» Articles » PMID: 33984421

Low-dose Candesartan Prevents Schizophrenia-like Behavioral Alterations in a Neurodevelopmental Two-hit Model of Schizophrenia

Abstract

Schizophrenia is a severe mental disorder with complex etiopathogenesis. Based on its neurodevelopmental features, an animal model induced by "two-hit" based on perinatal immune activation followed by peripubertal unpredictable stress was proposed. Sex influences the immune response, and concerning schizophrenia, it impacts the age of onset and symptoms severity. The neurobiological mechanisms underlying the influence of sex in schizophrenia is poorly understood. Our study aimed to evaluate sex influence on proinflammatory and oxidant alterations in male and female mice exposed to the two-hit model of schizophrenia, and its prevention by candesartan, an angiotensin II type 1 receptor (AT1R) blocker with neuroprotective properties. The two-hit model induced schizophrenia-like behavioral changes in animals of both sexes. Hippocampal microglial activation alongside the increased expression of NF-κB, and proinflammatory cytokines, namely interleukin (IL)-1β and TNF-α, were observed in male animals. Conversely, females presented increased hippocampal and plasma levels of nitrite and plasma lipid peroxidation. Peripubertal administration of low-dose candesartan (0.3 mg/kg PO) prevented behavioral, hippocampal, and systemic changes in male and female mice. While these results indicate the influence of sex on inflammatory and oxidative changes induced by the two-hit model, candesartan was effective in both males and females. The present study advances the neurobiological mechanisms underlying sex influence in schizophrenia and opens new avenues to prevent this devasting mental disorder.

Citing Articles

Association between psychiatric disorders and intracranial aneurysms: evidence from Mendelian randomization analysis.

Bao S, Xing Z, He S, Hu X, Yang J, Zhou B Front Neurol. 2024; 15:1422984.

PMID: 39131049 PMC: 11312739. DOI: 10.3389/fneur.2024.1422984.


Is It Time for a Paradigm Shift in the Treatment of Schizophrenia? The Use of Inflammation-Reducing and Neuroprotective Drugs-A Review.

Messina A, Concerto C, Rodolico A, Petralia A, Caraci F, Signorelli M Brain Sci. 2023; 13(6).

PMID: 37371435 PMC: 10296023. DOI: 10.3390/brainsci13060957.


Targeting the Renin-Angiotensin System (RAS) for Neuropsychiatric Disorders.

de Miranda A, Macedo D, Rocha N, Teixeira A Curr Neuropharmacol. 2022; 22(1):107-122.

PMID: 36173067 PMC: 10716884. DOI: 10.2174/1570159X20666220927093815.


Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects.

Carnovale C, Perrotta C, Baldelli S, Cattaneo D, Montrasio C, Barbieri S Cardiovasc Res. 2022; 119(3):647-667.

PMID: 35895876 PMC: 10153433. DOI: 10.1093/cvr/cvac110.